Average Insider

Where insiders trade, we follow

$LGND
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
Healthcare
Sector
Biotechnology
Industry
Todd C. Davis
CEO
68
Employees
$301.71
Current Price
$3.74B
Market Cap
52W Low$175.89
Current$301.7183.5% above low, 16.5% below high
52W High$326.63

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00--All Sells
Sells22$798,836.202,500
2 weeksBuys00--All Sells
Sells38$1,758,977.185,500
1 monthBuys00--All Sells
Sells428$4,091,466.9212,893
2 monthsBuys00--All Sells
Sells434$5,611,812.7917,893
3 monthsBuys00--All Sells
Sells440$7,384,247.1824,093
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Nov 12, 2026
Zimmermann Martine
Director
Sale2,000$318.17$636,336.20View Details
Nov 12, 2026
KOZARICH JOHN W
Director
Sale500$325.00$162,500.00View Details
Nov 10, 2026
Aryeh Jason
Director
Sale500$320.20$160,100.00View Details
Nov 10, 2026
Aryeh Jason
Director
Sale500$319.99$159,995.00View Details
Nov 10, 2026
Aryeh Jason
Director
Sale646$320.00$206,720.00View Details
Nov 10, 2026
Aryeh Jason
Director
Sale10$320.02$3,200.20View Details
Nov 10, 2026
Aryeh Jason
Director
Sale844$320.00$270,075.78View Details
Nov 10, 2026
Aryeh Jason
Director
Sale500$320.10$160,050.00View Details
Nov 4, 2026
Aryeh Jason
Director
Sale282$319.99$90,237.18View Details
Nov 2, 2026
Reardon Andrew
CLO&Secretary
Sale320$319.97$102,390.34View Details
Nov 2, 2026
Reardon Andrew
CLO&Secretary
Sale490$310.61$152,201.30View Details
Nov 2, 2026
Reardon Andrew
CLO&Secretary
Sale522$309.91$161,772.86View Details
Nov 2, 2026
Reardon Andrew
CLO&Secretary
Sale520$311.72$162,093.26View Details
Nov 2, 2026
Reardon Andrew
CLO&Secretary
Sale440$318.73$140,239.66View Details
Nov 2, 2026
Reardon Andrew
CLO&Secretary
Sale283$307.39$86,991.85View Details
Nov 2, 2026
Reardon Andrew
CLO&Secretary
Sale634$312.85$198,349.63View Details
Nov 2, 2026
Reardon Andrew
CLO&Secretary
Sale403$313.75$126,440.93View Details
Nov 2, 2026
Reardon Andrew
CLO&Secretary
Sale200$321.44$64,288.00View Details
Nov 2, 2026
Reardon Andrew
CLO&Secretary
Sale120$323.14$38,777.20View Details
Nov 2, 2026
Reardon Andrew
CLO&Secretary
Sale280$317.91$89,013.99View Details

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
Nov 5, 2026
EPS
Estimated$2.26
ActualN/A
Revenue
Estimated$77.95M
ActualN/A
1 more earnings records available โ€” create a free account to see 12 months of history

Related Activity

Cross-company insider connections and cluster buy signals
Version: v26.11.1